Tiziana Life Sciences Ltd. announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for intranasal foralumab to be studied in Alzheimer's disease. Foralumab could be a potentially groundbreaking treatment for Alzheimer's disease, given it targets the disease's underlying pathology by addressing the resulting neuroinflammation caused by the accumulation of toxic proteins in the brain.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7801 USD | -7.25% | +17.13% | +39.30% |
Apr. 23 | Sector Update: Health Care Stocks Rise in Afternoon Trading | MT |
Apr. 23 | Tiziana Life Sciences Says US FDA Allows Enrollment of 20 More Patients in Foralumab MS Expanded Access Program | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+39.30% | 78.25M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- TLSA Stock
- News Tiziana Life Sciences Ltd
- Tiziana Life Sciences Ltd. Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer's Disease